Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2019-01-24 Director's Dealing
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2019-01-24 English
4
Director's Dealing
2019-01-24 English
4
Director's Dealing
2019-01-24 English
4
Director's Dealing
2019-01-24 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a public offering of common stock by PTC Therapeutics, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5) and includes registration fee calculations and offering details. This type of document is a capital markets filing related to fundraising activities and changes in capital structure. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a full prospectus supplement.
2019-01-24 English
424B5
Capital/Financing Update Classification · 95% confidence The document is identified as a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) and includes detailed information about a public offering of common stock by PTC Therapeutics, Inc. It discusses the terms of the offering, underwriting details, risk factors, use of proceeds, and other related information typical of a securities offering document. The presence of a registration statement number and references to the Securities and Exchange Commission (SEC) further confirm this is a filing related to a capital raising event. This type of document is not a financial report, earnings release, or management discussion, but rather a detailed disclosure related to a capital/financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual prospectus supplement, not merely an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification and content.
2019-01-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.